Muscle composition measured by CT scan is a measurable predictor of overall survival in advanced ovarian cancer

Gynecologic Oncology

Volumn 142, Issue 2, 2016, Pages 311-316

  Kumar, Amanika ^a   Moynagh, Michael R ^a   Multinu, Francesco ^a   Cliby, William A ^a   McGree, Michaela E ^a   Weaver, Amy L ^a   Young, Phillip M ^a   Bakkum Gamez, Jamie N ^a   Langstraat, Carrie L ^a   Dowdy, Sean C ^a   Jatoi, Aminah ^a   Mariani, Andrea ^a  

^a MAYO CLINIC   (United States)

Author keywords

Body composition; Ovarian cancer; Overall survival; Sarcopenia; Skeletal muscle attenuation

Indexed keywords

ADULT; ADVANCED CANCER; ARTICLE; ATTENUATION; BODY COMPOSITION; CANCER SURGERY; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MUSCLE MASS; OVARY CARCINOMA; OVERALL SURVIVAL; PATIENT COUNSELING; PILOT STUDY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RISK FACTOR; SARCOPENIA; SKELETAL MUSCLE; SURVIVAL RATE; AGED; CANCER STAGING; COMPLICATION; DIAGNOSTIC IMAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY;

AGED; BODY COMPOSITION; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; MUSCLE, SKELETAL; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; SARCOPENIA;

EID: 84976486203     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2016.05.027     Document Type: Article

References (25)

1. [1] American Cancer Society, Cancer Facts & Figs. 2016, American Cancer Society, Atlanta, 2016.
2. [2] Fearon, K., Strasser, F., Anker, S.D., et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 12 (2011), 489–495.
3. [3] Englesbe, M.J., Lee, J.S., He, K., Fan, L., Schaubel, D.E., Sheetz, K.H., et al. Analytic morphomics, core muscle size, and surgical outcomes. Ann. Surg. 256 (2012), 255–261.
4. [4] Psutka, S.P., Carrasco, A., Schmit, G.D., Moynagh, M.R., Boorjian, S.A., Frank, I., et al. Sarcopenia in patients with bladder cancer undergoing radical cystectomy: impact on cancer-specific and all-cause mortality. Cancer 120 (2014), 2910–2918.
5. [5] Martin, L., Birdsell, L., MacDonald, N., Reiman, T., Clandinin, M.T., McCargar, L.J., et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J. Clin. Oncol. 31 (2013), 1539–1547.
6. [6] Prado, C.M.M., Wells, J.C.K., Smith, S.R., Stephan, B.C.M., Siervo, M., Sarcopenic obesity: a critical appraisal of the current evidence. Clin. Nutr. 31 (2012), 583–601.
7. [7] Prado, C.M.M., Baracos, V.E., Lieffers, J.R., McCargar, L.J., Reiman, T., Sawyer, M.B., et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 9 (2008), 629–635.
8. [8] Tan, B.H.L., Birdsell, L.A., Martin, L., Baracos, V.E., Fearon, K.C.H., Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin. Cancer Res. 15 (2009), 6973–6979.
9. [9] Baracos, V., Kazemi-Bajestani, S.M.R., Clinical outcomes related to muscle mass in humans with cancer and catabolic illnesses. Int. J. Biochem. Cell Biol. 45 (2013), 2302–2308.
10. [10] Morley, J.E., Vellas, B., van Kan, G.A., et al. Frailty consensus: a call to action. J. Am. Med. Assoc. 14 (2013), 392–397.
11. [11] Torres, M.L., Hartmann, L.C., Cliby, W.A., Kalli, K.R., Young, P.M., Weaver, A.L., et al. Nutritional status, CT body composition measures, and survival in ovarian cancer. Gynecol. Oncol. 129 (2013), 548–553.
12. [12] Mourtzakis, M., Prado, C.M.M., Lieffers, J.R., Reiman, T., McCargar, L.J., Baracos, V.E., A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl. Physiol. Nutr. Metab. 33 (2008), 997–1006.
13. [13] Goodpaster, B.H., Skeletal muscle attenuation determined by computed tomography is associated with skeletal muscle lipid content. J. Appl. Physiol. 89 (2000), 104–110.
14. [14] Kumar, A., Janco, J.M., Mariani, A., Bakkum-Gamez, J.N., Langstraat, C.L., Weaver, A.L., et al. Risk-prediction model of severe postoperative complications after primary debulking surgery for advanced ovarian cancer. Gynecol. Oncol. 140 (2016), 15–21.
15. [15] Therneau, T.M., Atkinson, E.J., Technical Report Series No. 61, An Introduction to Recursive Partitioning Using the RPART Routines. 1997, Department of Health Science Research, Mayo Clinic, Rochester, Minnesota.
16. [16] Kuroki, L.M., Mangano, M., Allsworth, J.E., Menias, C.O., Massad, L.S., Powell, M.A., et al. Pre-operative assessment of muscle mass to predict surgical complications and prognosis in patients with endometrial cancer. Ann. Surg. Oncol. 22 (2014), 972–979.
17. [17] Sabel, M.S., Lee, J., Cai, S., Englesbe, M.J., Holcombe, S., Wang, S., Sarcopenia as a prognostic factor among patients with stage III melanoma. Ann. Surg. Oncol. 18 (2011), 3579–3585.
18. [18] Antoun, S., Lanoy, E., Iacovelli, R., Albiges-Sauvin, L., Loriot, Y., Merad-Taoufik, M., et al. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. Cancer 119 (2013), 3377–3384.
19. [19] Aubrey, J., Esfandiari, N., Baracos, V.E., Buteau, F.A., Frenette, J., Putman, C.T., et al. Measurement of skeletal muscle radiation attenuation and basis of its biological variation. Acta Physiol. 210 (2014), 489–497.
20. [20] Antoun, S., Baracos, V.E., Birdsell, L., Escudier, B., Sawyer, M.B., Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann. Oncol. 21 (2010), 1594–1598.
21. [21] Slaughter, K.N., Thai, T., Penaroza, S., Benbrook, D.M., Thavathiru, E., Ding, K., et al. Measurements of adiposity as clinical biomarkers for first-line bevacizumab-based chemotherapy in epithelial ovarian cancer. Gynecol. Oncol. 133 (2014), 11–15.
22. [22] Melov, S., Tarnopolsky, M.A., Beckman, K., Felkey, K., Hubbard, A., Resistance exercise reverses aging in human skeletal muscle. Wenner, P., (eds.) PLoS ONE, 2, 2007, e465.
23. [23] Latres, E., Pangilinan, J., Miloscio, L., Bauerlein, R., Na, E., Potocky, T.B., et al. Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice. Skelet. Muscle Skelet. Muscle, 2015, 1–13.
24. [24] Dutt, V., Gupta, S., Dabur, R., Injeti, E., Mittal, A., Skeletal muscle atrophy: potential therapeutic agents and their mechanisms of action. Pharmacol. Res. 99 (2015), 86–100.
25. [25] Ma, J.D., Heavey, S.F., Revta, C., Roeland, E.J., Novel investigational biologics for the treatment of cancer cachexia. Expert. Opin. Biol. Ther. 14 (2015), 1113–1120.